Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut effective July 1, 2026, and will reopen 48 hours after the announcement of the un-audited financial results for the quarter ended June 30, 2026. The date for the board meeting to consider these financial results will be communicated separately.

Thyrocare Technologies Ltd has informed the exchange that it has sent a letter to its members providing a web-link to the Notice of its 26th Annual General Meeting (AGM) and the Annual Report for the financial year 2025-26. This communication is directed to members who have not registered their email addresses. The AGM is scheduled for June 30, 2026. The filing also details the record date for final dividend (June 23, 2026), e-voting period (June 26-29, 2026), and dividend payment date (on or before July 29, 2026).

Thyrocare Technologies Limited has announced Tuesday, June 23, 2026, as the record date for determining shareholder eligibility for the final dividend for the Financial Year ended March 31, 2026. The dividend, recommended at ₹7.00 per equity share, is subject to shareholder approval at the upcoming Annual General Meeting (AGM) scheduled for Tuesday, June 30, 2026. If declared, the dividend payment is expected on or before Wednesday, July 29, 2026. This announcement follows the Board's recommendation on May 7, 2026, and adheres to SEBI Listing Regulations.

Thyrocare Technologies Ltd has submitted its Business Responsibility and Sustainability Reporting (BRSR) for the financial year 2025-26, as required by SEBI Listing Regulations. The report details the company's corporate identity, business activities (98.66% from diagnostic services), operational locations, employee data, and market reach, including a 0.05% contribution from exports. The BRSR is submitted on a standalone basis and forms part of the company's Annual Report.

Thyrocare Technologies Limited has announced its 26th Annual General Meeting (AGM) for the financial year 2025-26. The AGM is scheduled for Tuesday, June 30, 2026, at 11:00 AM IST at their Navi Mumbai corporate office. The company will distribute its Annual Report, including the AGM Notice and Business Responsibility and Sustainability Report, to its members. Members have the option for remote e-voting from June 26 to June 29, 2026, or voting at the AGM venue. The cut-off date for eligibility to vote is June 23, 2026. The annual report highlights the company's focus on diagnostic excellence, accessibility, affordability, and expansion.

Thyrocare Technologies Ltd has announced its 26th Annual General Meeting (AGM) scheduled for Tuesday, June 30, 2026. The company has also released its Annual Report for the financial year 2025-26, which includes the AGM notice and the Business Responsibility and Sustainability Report. Members can participate through remote e-voting, which will be open from June 26 to June 29, 2026, or by voting at the AGM venue. The cut-off date for eligibility to vote is June 23, 2026. The annual report highlights the company's progress in diagnostics, focusing on accessibility, affordability, and innovation.

Thyrocare Technologies Ltd's Board of Directors has recommended a final dividend of ₹7.00 per equity share for FY26, subject to shareholder approval at the AGM. If approved, the dividend will be paid within 30 days of the AGM. The company has already paid an interim dividend of ₹7.00 per share (₹2.33 post bonus adjustment). The total dividend for FY26 aggregates to ₹9.33 per share (post bonus adjustment). The board also approved the appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for five years and re-appointed Rahul Franklin Guha as Chairman, MD & CEO for five years.

Thyrocare Technologies Ltd's Board of Directors has recommended a final dividend of ₹7.00 per equity share for FY26, subject to shareholder approval at the AGM. If approved, the dividend will be paid within 30 days of the AGM. The company has already paid an interim dividend of ₹7.00 per share (pre-bonus). The board also approved the appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for five years and re-appointed Rahul Franklin Guha as Chairman, MD & CEO for five years, and appointed M/s. Jitender Navneet & Co., Cost Accountants as the Cost Auditor of the Company for the Financial Year 2026-27.

Thyrocare Technologies Ltd's Board of Directors has recommended a final dividend of ₹7.00 per equity share for FY26, subject to shareholder approval at the AGM. If approved, the dividend will be paid within 30 days of the AGM. The company has already paid an interim dividend of ₹7.00 per share (pre-bonus). The board also approved the appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for five years and re-appointed Rahul Franklin Guha as Chairman, MD & CEO for five years, and appointed M/s. Jitender Navneet & Co., Cost Accountants as the Cost Auditor of the Company for the Financial Year 2026-27.

Thyrocare Technologies Ltd's Board of Directors has recommended a final dividend of ₹7.00 per equity share for FY26, subject to shareholder approval at the AGM. If approved, the dividend will be paid within 30 days of the AGM. The company has already paid an interim dividend of ₹7.00 per share (pre-bonus), making the total dividend ₹9.33 per share (post-bonus). Additionally, Price Waterhouse Chartered Accountants LLP has been appointed as the statutory auditors for a five-year term, and M/s. Jitender Navneet & Co. as the Cost Auditor for FY27. Mr. Rahul Franklin Guha has been re-appointed as Chairman, Managing Director & CEO for another five years.